Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5100-5106

  Saleem, Ahamed ^a   Ibrahim, Nageatte ^a   Patel, Milan ^a   Li, Xi Guang ^a   Gupta, Elora ^a   Mendoza, John ^b   Pantazis, Panayotis ^b   Rubin, Eric H ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Stehlin Found for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ARTICLE; CELL SURVIVAL; CODON; CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL NUCLEUS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; LEUKEMIA; PHENOTYPE; POINT MUTATION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0030663710     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
2. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
3. Froelich-Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
4. Liu, L. F. Anticancer drugs that convert DNA topoisomerases into DNA damaging agents. In: N. R. Cozzarelli and J. C. Wang (ed.), DNA Topology and Its Biological Effects, pp. 371-389. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1990.
5. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
6. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
7. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol., 23 (Suppl.): 3-10, 1996.
8. Beck, W. T., Danks, M. K., Wolverton, J. S., Chen, M., Granzen, B., Kim, R., and Parker Suttle, D. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. In: L. F. Liu (ed.), DNA Topoisomerases: Topoisomerase-targeting Drugs, pp. 145-169. San Diego: Academic Press, 1994.
9. Rubin, E. H., Li, T., Duan, P., and Liu, L. F. Cellular resistance to topoisomerase poisons. In: W. N. Hait (ed.), Drug Resistance, pp. 243-260. Norwell, MA: Kluwer Academic Publishers, 1996.
10. Ferguson, P. J., Fisher, M. H., Stephenson, J., Li, D., Zhou, B., and Cheng, Y. C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res., 48: 5956-5964, 1988.
11. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48: 6404-6410, 1988.
12. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol., 38: 471-480, 1990.
13. Sugimoto, Y., Tsukahara, S., Oh-haia, T., Liu, L. F., and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50: 7962-7965, 1990.
14. Woessner, R. D., Eng, W., Hofmann, G. A., Rieman, D. J., McCabe, F. L., Hertzberg, R. P., Mattern, M. R., Tan, K. B., and Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4: 481-488, 1992.
15. Chang, J., Dethlefsen, L. A., Barley, L. R., Zhou, B., and Cheng, Y. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
16. Tanizawa, A., and Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res., 52: 1848-1854, 1992.
17. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B., and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem., 269: 2433-2439, 1994.
18. Tan, K. B., Mattern, M. R., Eng, W., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase I inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
19. Lefevre, D., Riou, J. F., Ahomadegbe, J. C., Zhou, D., Bernard, J., and Riou, G. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line: decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S-transferase. Biochem. Pharmacol., 41: 1967-1979, 1991.
20. Riou, J., Grondard, L., Petitgenet, O., Abitbol, M., and Lavelle, F. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin. Biochem. Pharmacol., 46: 851-861, 1993.
21. Beidler, D. R., Chang, J. Y., Zhou, B. S., and Cheng, Y. C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res., 56: 345-353, 1996.
22. Eckardt, J. R., Burris, H. A., Von Hoff, D. D., Rodriguez, G. I., Fields, S. M., Rothenberg, M. L., Moore, T. D., Hodges, S., Weiss, G. R., Cobb, P., Rinaldi, D., Kuhn, J. G., Ford, J., and Ganapathi, R. Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc. Am. Soc. Clin. Oncol., 13: 141 (A358), 1994.
23. Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer, D., and Kufe, D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res., 1: 269-276, 1995.
24. Toppmeyer, D., Gupta, E., Saleem, A., Zamek, R., Much, J., Ibrahim, N., Bindi, M., Haluska, P., Li, X-G., Goodin, S., Aisner, J., Natelson, E., Giovanella, B., and Rubin, E. A phase I pharmacokinetic and pharmacodynamic study of camptothecin and etoposide in patients with advanced malignancies. Proc. Am. Soc. Oncol., 16: 203 (A713), 1997.
25. Matsumoto, N., Nakano, S., Esaki, T., Tatsumoto, T., Fujishima, H., Baba, E., Nakamura, M., and Niho, Y. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res., 15: 405-410, 1995.
26. Eder, J. P., Ikebe, M., Wong, E., Rizvi, N., Chen, V. T-W., and Teicher, B. A. CPT-11/topoisomerase II (topo II) inhibitor combination therapy: molecular pharmacology and therapeutic response. Proc. Am. Assoc. Cancer Res., 37: 430, 1996.
27. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and Berger, N. A. Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in a schedule-dependent process. Cancer Res., 57: 1425-1428, 1997.
28. Pantazis, P., Hinz, H. R., Mendoza, J. T., Kozielski, A. J., Williams, L. J., Stehlin, J. S., and Giovanella, B. C, Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res., 52: 3980-3987, 1992.
29. Saleem, A., Datta, R., Yuan, Z-M., Kharbanda, S., and Kufe, D. Involvement of stress-activated protein kinase in the cellular response to 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ., 6: 1651-1658, 1995.
30. Boege, F., Andersen, A., Jensen, S., Zeidler, R., and Kreipe, H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIa: delineation of a carboxy-terminal epitope with peptide antibodies. Am. J. Pathol., 146: 1302-1308, 1995.
31. Rubin, E., Kharbanda, S., Gunji, H., and Kufe, D. Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol. Pharmacol., 39: 697-701, 1991.
32. Wasserman, R. A., Austin, C. A., Fisher, L. M., and Wang, J. C. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res., 53: 3591-3596, 1993.
33. Tamura, H., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Patterson, E., Keene, J. D., Okada, K., Kjeldsen, E., Nishikawa, K., and Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res., 19: 69-75, 1990.
34. Brill, S. J., DiNardo, S., Voelkel-Meiman, K., and Sternglanz, R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (Lond.), 326: 414-416, 1987.
35. Kim, R. A., and Wang, J. C. Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae. J. Mol. Biol., 208: 257-267, 1989.
36. Morham, S. G., Kluckman, K. D., Voulomanos, N., and Smithies, O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol., 16: 6804-6809, 1996.
37. Bugg, B. Y., Danks, M. K., Beck, W. T., and Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88: 7654-7658, 1991.
38. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F. D., and Zwelling, L. A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res., 51: 4729-4731, 1991.
39. Lee, M., Wang, J. C., and Beran, M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol., 223: 837-843, 1992.
40. de Jong, S., Kooistra, A. J., de Vries, E. G. E., Mulder, N. H., and Zijlstra, J. G. Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res., 53: 1064-1071, 1993.
41. Hashimoto, S., Danks, M. K., Chatterjee, S., Beck, W. T., and Berger, N. A. A novel point mutation in the 3′ flanking region of the DNA-binding domain of topoisomerase IIa associated with acquired resistance to topoisomerase II active agents. Oncol. Res., 7: 21-29, 1995.
42. r 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res., 55: 2129-2134, 1995.
43. Andoh, T., Nishizawa, M., Hida, T., Ariyoshi, Y., Takahashi, T., and Ueda, R, Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer lines established from a refractory tumor of a patient and by in vitro selection. Oncol. Res., 8: 229-238, 1996.
44. Hsiung, Y., Jannatipour, M., Rose, A., McMahon, J., Duncan, D., and Nitiss, J. L. Functional expression of human topoisomerase IIa in yeast: mutations at amino acids 450 or 803 of topoisomerase IIa result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res., 56: 91-99, 1996.
45. Harker, W. G., Slade, D. L., Parr, R. L., Feldhoff, P. W., Sullivan. D. M., and Holguin, M. H. Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res., 55: 1707-1716, 1995.
46. Chen, M., and Beck, W. T. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res., 7: 103-111, 1995.
47. Hanai, R., Caron, P. R., and Wang, J. C. Human TOP3: a single copy gene encoding DNA topoisomerase II. Proc. Natl. Acad. Sci. USA, 93: 3653-3657, 1996.
48. Yang, C-H. J., Horton, J. K., Cowan, K., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
49. Kusumoto, H., Rodgers, Q. E., Boege, F., Raimondi, S. C., and Beck, W. T. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res., 56: 2573-2583, 1996.
50. Kreis, W., Budman, D. R., Vinciguerra, V., Hock, K., Baer, J., Ingram, R., Schacter, L. P., and Fields, S. Z. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother. Pharmacol., 38: 378-384, 1996.
51. Kotoh, S., Naito, S., Yokomizo, A., Kumazawa, J., Asakuno, K., Kohno, K., and Kuwano, M. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res., 54: 3248-3252, 1994.
52. Schabel, F. M., Trader, M. W., Laster, W. R., Corbett, T. H., and Griswold, D. P. cis-dichloro-diammineplatinum (II): Combination in chemotherapy and cross resistance in studies with tumors of mice. Cancer Treat. Rep., 63: 1459-1473, 1979.
53. Eder, J. P., Teicher, B. A., Holden, S. A., Senator, E., Cathcart, K. N. S., and Schnipper, L. E. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and an epipodophyllotoxin-resistant subline. Cancer Chemother. Pharmacol., 26: 423-428, 1990.
54. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S., and Miura, Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50: 604-610, 1992.
55. Minagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H., and Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res., 85: 966-971, 1994.
56. Fukuda, M., Nishio, K., Kanzawa, F., Ogasawara, H., Ishida, T., Arioka, H., Bojanowski, K., Oka, M., and Saijo, N. Synergism between cisplalin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res., 56: 789-793, 1996.
57. Rowinsky, E. K., Kaufmann, S. H., Baker, S. D., Grochow, E. B., Chen, T-L., Peereboom, D., Bowling, M. K., Sartorius, S. E., Ettinger, D. S., Forastiere, A. A., and Donehower, R. C. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol., 14: 3074-3084, 1996.
58. Tsai-Pflugfelder, M., Liu, L. F., Liu. A. A., Tewey, K. M., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C. M., and Wang, J. C. Cloning and sequencing of cDNA encoding human topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. USA, 85: 7177-7181, 1988.
59. Jenkins, J. R., Ayton, P., Jones, T., Davies, S. L., Simmons, D. L., Harris, A. L., Sheer, D., and Hickson, I. D. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res., 20: 5587-5592, 1992.